Literature DB >> 25869725

Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.

U Creutzig1, M N Dworzak2, M Zimmermann1, J-P Bourquin3, B Gruhn4, G Fleischhack5, N Graf6, T Klingebiel7, B Kremens5, T Lehrnbecher7, C von Neuhoff1, A V Stackelberg8, J Starý9, D Reinhardt1,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25869725     DOI： 10.1038/leu.2015.94

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.

Authors:  Isabelle Hubeek; Godefridus J Peters; Richard Broekhuizen; Christian M Zwaan; Patricia Kaaijk; Elisabeth S van Wering; Brenda E S Gibson; Ursula Creutzig; Gritta E Janka-Schaub; Monique L den Boer; Rob Pieters; Gertjan J L Kaspers
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

2.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

Authors:  S Seto; C J Carrera; M Kubota; D B Wasson; D A Carson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

Authors:  Jerzy Holowiecki; Sebastian Grosicki; Sebastian Giebel; Tadeusz Robak; Slawomira Kyrcz-Krzemien; Kazimierz Kuliczkowski; Aleksander B Skotnicki; Andrzej Hellmann; Kazimierz Sulek; Anna Dmoszynska; Janusz Kloczko; Wieslaw W Jedrzejczak; Barbara Zdziarska; Krzysztof Warzocha; Krystyna Zawilska; Mieczyslaw Komarnicki; Marek Kielbinski; Beata Piatkowska-Jakubas; Agnieszka Wierzbowska; Malgorzata Wach; Olga Haus
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

4.  Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.

Authors:  R A Krance; C A Hurwitz; D R Head; S C Raimondi; F G Behm; K R Crews; D K Srivastava; H Mahmoud; W M Roberts; X Tong; R L Blakley; R C Ribeiro
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

5.  Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.

Authors:  U Creutzig; M Dworzak; M Zimmermann; J-P Bourquin; B Gruhn; G Fleischhack; N Graf; T Klingebiel; B Kremens; T Lehrnbecher; C von Neuhoff; A von Stackelberg; J Stray; D Reinhardt
Journal:  Klin Padiatr       Date:  2015-05-18       Impact factor: 1.349

6.  Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Authors:  Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Gudrun Fleischhack; Norbert Graf; Thomas Klingebiel; Bernhard Kremens; Thomas Lehrnbecher; Christine von Neuhoff; Jörg Ritter; Annette Sander; André Schrauder; Arend von Stackelberg; Jan Starý; Dirk Reinhardt
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

7.  Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.

Authors:  V Gandhi; E Estey; M J Keating; A Chucrallah; W Plunkett
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

8.  2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.

Authors:  V M Santana; J Mirro; C Kearns; M J Schell; W Crom; R L Blakley
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

9.  Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.

Authors:  J Holowiecki; S Grosicki; T Robak; S Kyrcz-Krzemien; S Giebel; A Hellmann; A Skotnicki; W W Jedrzejczak; L Konopka; K Kuliczkowski; B Zdziarska; A Dmoszynska; B Marianska; A Pluta; K Zawilska; M Komarnicki; J Kloczko; K Sulek; O Haus; B Stella-Holowiecka; W Baran; B Jakubas; M Paluszewska; A Wierzbowska; M Kielbinski; K Jagoda
Journal:  Leukemia       Date:  2004-05       Impact factor: 11.528

Review 10.  Older and new purine nucleoside analogs for patients with acute leukemias.

Authors:  Pawel Robak; Tadeusz Robak
Journal:  Cancer Treat Rev       Date:  2013-04-06       Impact factor: 12.111
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.